

IGF1R expression and survival in non-small cell lung cancer patients

Table S1. Result of the methodological assessment by the European lung cancer working party score

Subgroups	No. of studies (%)	Global score % (Mean [95% CI])	P-values
Publication year			
Before 2010	7 (41.2%)	59.43 (53.02-65.84)	0.332
After 2010	10 (58.8%)	62.81 (57.96-67.65)	
Results			
Positive	4 (23.5%)	62.59 (48.23-76.94)	0.783
Negative	4 (23.5%)	62.84 (59.22-66.47)	
N*	8 (53.0%)	60.26 (54.42-66.11)	
Patient number			
< 150	6 (35.3%)	60.70 (56.91-64.49)	0.762
≥ 150	11 (64.7%)	61.80 (56.28-67.34)	
Ethnicity			
Asian	13 (76.5%)	61.81 (58.17-65.45)	0.681
non-Asian	4 (23.5%)	60.13 (44.12-76.14)	

Positive: Studies identifying IGF1R positivity as a significant poor prognosis factor. Negative: Studies reporting IGF1R positivity as a good prognosis factor. N*: Studies reporting IGF1R positivity as non-significant association with poor prognosis.

Table S2. IGF1R expression and clinical outcomes in patients with NSCLC

Author & year	Overall survival						Disease-free survival					
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis		
	HR estimation	HR	95% CI	HR estimation	HR	95% CI	HR estimation	HR	95% CI	HR estimation	HR	95% CI
Gately K. 2013	K-M	0.84	0.50-1.43									
Zhang XY. 2013							HR	1.11	0.86-1.44			
Xu C. 2013							K-M	1.54	1.02-2.32	HR	1.25	0.79-1.96
Ludovini V. 2013	HR	1.55	0.93-2.59				HR	1.59	0.91-2.77			
Yamamoto T. 2012				HR	2.32	1.22-4.44						
Tsuta K. 2012	K-M	0.98	0.75-1.28									
Kim YH. 2012	K-M	0.61	0.31-1.23				K-M	0.78	0.47-1.3			
Kim JS. 2012	K-M	1.02	0.79-1.31				K-M	1.29	1.02-1.63			
Kikuchi R. 2011				HR	0.56	0.32-0.95						
Nakagawa M. 2011							HR	2.68	1.27-5.68	HR	2.51	1.18-5.44
Dziadziuszko R. 2010	HR	0.70	0.53-0.90	HR	0.75	0.57-0.99						
Ning XH. 2010	K-M	0.96	0.35-2.67									
Cappuzzo F. 2009	K-M	0.94	0.78-1.13									
Chang MH. 2009	K-M	0.90	0.62-1.30									
Gong YX. 2009	K-M	1.05	0.67-1.64									
Lee CY. 2008	K-M	4.90	0.37-65.30									
Cappuzzo F. 2006	K-M	0.51	0.29-0.87	HR	0.43	0.23-0.80						

IGF1R: Insulin-like growth factor-1 receptor; K-M: Kaplan-Meier curve; HR: Hazard ratio.

IGF1R expression and survival in non-small cell lung cancer patients

Table S3. Information of antibody sources

Author	Year	Species	Suppliers	Dilution
Gately K.	2013	Rabbit monoclonal	Ventana Medical Systems, Tucson, AZ	1:100
Zhang XY	2013	Mouse	BioSource International, Camarillo, USA	1:50
Xu C.	2013	Rabbit	Abcam, Cambridge, UK	1:100
Ludovini V.	2013	Mouse	Lab Vision Neomarkers, USA	1:50
Yamamoto T.	2012	Rabbit polyclonal	Signalway Antibody, Pearland, USA	1:100
Tsuta K.	2012	Rabbit monoclonal	Ventana Medical Systems, Tucson, AZ	NA
Kim YH	2012	Rabbit monoclonal	Ventana Medical Systems, Tucson, AZ	1:1
Kim JS	2012	NA	Cell Signaling Technology, Danvers, MA	NA
Kikuchi R.	2011	Rabbit polyclonal	Cell Signaling Technology, Danvers, MA	1:100
Nakagawa M.	2011	Mouse monoclonal	Abcam, Cambridge, USA	1:500
Dziadziuszko R.	2010	NA	Ventana Medical Systems, Tucson, AZ	NA
Ning XH	2010	Rabbit	Boster, Wuhan, CHN	1:50
Cappuzzo F.	2009	NA	Novus Biologicals, Littleton, CO	NA
Chang MH	2009	Mouse monoclonal	Abcam, Cambridge, UK	1:1000
Gong YX	2009	Rabbit monoclonal	Ventana-Roche, Tucson, AZ	NA
Lee CY	2008	Mouse monoclonal	BioSource International, Camarillo, USA	1:50
Cappuzzo F.	2006	Mouse	Novus Biologicals, Littleton, CO	1:50

NA: Not available.